HANOVER
Cancer Incidence by Sex, 1993 - 1997
Expected and Observed Case Counts, with Standardized Incidence Ratios

| | Exp | <u>Obs</u> | SIR | | Exp | <u>Obs</u> | <u>SIR</u> |
|---|-----------|------------|------------------|-------------------------|-------|------------|------------|
| Bladder, Urina | <u>ry</u> | | Melanoma of Skin | | | | |
| Male | 6.52 | 2 | NC* | Male | 4.43 | 5 | 113 |
| Female | 2.50 | 3 | NC* | Female | 3.59 | 5 | 139 |
| Total | 9.02 | 5 | 55 | Total | 8.03 | 10 | 125 |
| Brain and Other Central Nervous System | | | | Multiple Myeloma | | | |
| Male | 2.52 | 2 | NC* | Male | 1.27 | 1 | NC* |
| Female | 2.14 | 4 | NC* | Female | 1.21 | 1 | NC* |
| Total | 4.66 | 6 | 129 | Total | 2.48 | 2 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin's Lymphoma | | | |
| Male | 0.44 | 1 | NC* | Male | 5.79 | 4 | NC* |
| Female | 46.13 | 43 | 93 | Female | 4.91 | 5 | 102 |
| Total | 46.58 | 44 | 94 | Total | 10.71 | 9 | 84 |
| Cervix Uteri | | | | Oral Cavity and Pharynx | | | |
| | | | | Male | 5.01 | 3 | NC* |
| Female | 3.04 | 3 | NC* | Female | 2.31 | 2 | NC* |
| | | | | Total | 7.32 | 5 | 68 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 16.71 | 24 | 144 | | | | |
| Female | 15.92 | 17 | 107 | Female | 5.61 | 3 | NC* |
| Total | 32.63 | 41 | 126 | | | | |
| Esophagus | | | <u>Pancreas</u> | | | | |
| Male | 2.62 | 6 | 229 | Male | 2.66 | 1 | NC* |
| Female | 0.82 | 0 | NC* | Female | 2.69 | 1 | NC* |

| | Total | 3.44 | 6 | 175 | Total | 5.35 | 2 | NC* |
|--|--------|-------|----|-------------------|----------------------|--------------|--------|--------|
| Hodgkin's Disease | | | | | Prostate | | | |
| | Male | 1.25 | 1 | NC* | Male | 42.23 | 45 | 107 |
| | Female | 0.93 | 1 | NC* | | | | |
| | Total | 2.19 | 2 | NC* | | | | |
| Kidney and Renal Pelvis | | | | | Stomach | | | |
| | Male | 4.31 | 5 | 116 | Male | 2.90 | 1 | NC* |
| | Female | 2.53 | 0 | NC* | Female | 1.70 | 1 | NC* |
| | Total | 6.84 | 5 | 73 | Total | 4.59 | 2 | NC* |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | |
| | Male | 2.66 | 2 | NC* | Male | 1.78 | 6 | 337 #+ |
| | Female | 0.77 | 0 | NC* | | | | |
| | Total | 3.43 | 2 | NC* | | | | |
| <u>Leukemia</u> | | | | | Thyroid | | | |
| | Male | 3.10 | 5 | 161 | Male | 0.96 | 3 | NC* |
| | Female | 2.35 | 5 | 213 | Female | 2.44 | 1 | NC* |
| | Total | 5.45 | 10 | 183 | Total | 3.40 | 4 | NC* |
| Liver and Intrahepatic Bile Ducts | | | | | <u>Uteri, Corpus</u> | s and Uterus | s, NOS | |
| | Male | 1.45 | 0 | NC* | | | | |
| | Female | 0.56 | 0 | NC* | Female | 8.94 | 11 | 123 |
| | Total | 2.02 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | | |
| | Male | 22.62 | 13 | 57 #- | Male | 140.94 | 134 | 95 |
| | Female | 17.65 | 24 | 136 | Female | 138.28 | 142 | 103 |
| | Total | 40.27 | 37 | 92 | Total | 279.21 | 276 | 99 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for

this cancer

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- * = SIR and statistical significance not calculated when $\mathbf{Obs} < 5$
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels